Emerging haemostatic sprays: From material design to clinical translation

Haemostatic sprays have emerged as a transformative class of topical agents for the rapid control of bleeding in surgery, trauma, and endoscopy, particularly in settings where conventional approaches such as suturing, cauterisation, or mechanical compression are impractical. Delivered in a non-contact and conformal manner, these systems enable efficient coverage of irregular, deep, and non-compressible bleeding sites. Their haemostatic action arises from synergistic biochemical and physical mechanisms, including activation of the coagulation cascade, plasma absorption driven concentration of clotting factors, and formation of adhesive or barrier-type matrices at the wound surface. Commercial and non-commercial products such as Hemospray®, PuraStat®, Raplixa™, Ankaferd Blood-Stopper®, EndoClot®, OOZFIX™, and CMCS-COHA have demonstrated clinically meaningful reductions in bleeding, improved procedural visibility, and favourable patient outcomes across gastrointestinal, surgical, and trauma indications. Alongside these, a rapidly expanding portfolio of pre-clinical sprayable biomaterials spanning mineral, polysaccharide, protein, peptide, hydrogel, and nano-engineered platforms offers new opportunities to address unmet needs in non-compressible and complex haemorrhage. This review provides a comprehensive and integrated analysis of haemostatic sprays, covering material classes, mechanisms of action, clinical applications, and translational performance. Key challenges, including tissue irritation, thromboembolic risk, impaired visualisation, and limitations in adhesion or durability, are critically examined, together with emerging strategies to improve biocompatibility, targeting accuracy, and suitability for pre-hospital or low-resource settings. By synthesizing current clinical evidence with advances in biomaterial design and spray-delivery technologies, this review defines the present capabilities of haemostatic sprays and outlines a roadmap for their next-generation development. These innovations are poised to further enhance the safety, speed, and effectiveness of bleeding control in modern surgical and emergency care.

Authors

Institutions

Publication Details

Journal
Biomaterials Advances
Published
2026-03-03
DOI
https://doi.org/10.1016/j.bioadv.2026.214796
Primary Topic
Hemostasis and retained surgical items
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Emerging haemostatic sprays: From material design to clinical translation

Akriti Nepal, Hang Thu Ta, Nam-Trung Nguyen, Huyen Tran
Biomaterials Advances
Hemostasis and retained surgical items
article

Emerging haemostatic sprays: From material design to clinical translation

Akriti Nepal, Hang Thu Ta, Nam-Trung Nguyen, Huyen Tran
article en

Abstract

Haemostatic sprays have emerged as a transformative class of topical agents for the rapid control of bleeding in surgery, trauma, and endoscopy, particularly in settings where conventional approaches such as suturing, cauterisation, or mechanical compression are impractical. Delivered in a non-contact and conformal manner, these systems enable efficient coverage of irregular, deep, and non-compressible bleeding sites. Their haemostatic action arises from synergistic biochemical and physical mechanisms, including activation of the coagulation cascade, plasma absorption driven concentration of clotting factors, and formation of adhesive or barrier-type matrices at the wound surface. Commercial and non-commercial products such as Hemospray®, PuraStat®, Raplixa™, Ankaferd Blood-Stopper®, EndoClot®, OOZFIX™, and CMCS-COHA have demonstrated clinically meaningful reductions in bleeding, improved procedural visibility, and favourable patient outcomes across gastrointestinal, surgical, and trauma indications. Alongside these, a rapidly expanding portfolio of pre-clinical sprayable biomaterials spanning mineral, polysaccharide, protein, peptide, hydrogel, and nano-engineered platforms offers new opportunities to address unmet needs in non-compressible and complex haemorrhage. This review provides a comprehensive and integrated analysis of haemostatic sprays, covering material classes, mechanisms of action, clinical applications, and translational performance. Key challenges, including tissue irritation, thromboembolic risk, impaired visualisation, and limitations in adhesion or durability, are critically examined, together with emerging strategies to improve biocompatibility, targeting accuracy, and suitability for pre-hospital or low-resource settings. By synthesizing current clinical evidence with advances in biomaterial design and spray-delivery technologies, this review defines the present capabilities of haemostatic sprays and outlines a roadmap for their next-generation development. These innovations are poised to further enhance the safety, speed, and effectiveness of bleeding control in modern surgical and emergency care.

Biomaterials AdvancesVol. 184
Griffith University (AU), The Alfred Hospital (AU)
Industry, innovation and infrastructure
Openalex Percentile: Top 36%
Hemostasis and retained surgical items
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.